Electronic cigarette use, related health outcomes and policy interventions in the USA: a call for research to fill evidence gaps Authors: Tyler Nighbor, Shanshan Wang, Zheng Xue, Samuel Asare, Eva Orr-Souza, Minal Patel, Priti Bandi, Johann Lee Westmaas, Ahmedin Jemal, Nigar Nargis Published: 2026 ABSTRACT AbstractThe population-level health consequences of electronic cigarette (e-cigarette) use are heavily debated. This special communication provides updated evidence and identifies knowledge gaps across domains including: (1) health-related outcomes associated with e-cigarette use; (2) initiation and use of e-cigarettes among youth and young adults; (3) concurrent use of electronic and combustible cigarettes; (4) transitions from combustible cigarette use to exclusive e-cigarette use among adults who currently smoke cigarettes and (5) existing e-cigarette-related policy interventions. Literature was searched through PubMed and Medline for systematic reviews, scoping reviews, meta-analyses and primary research articles including emerging topics not covered in reviews published between 1 January 2017 and 1 January 2024. E-cigarette use is associated with several adverse acute health outcomes; there is currently insufficient longitudinal evidence to predict chronic health outcomes. Prevalence of e-cigarette use among youth is considerable and may be associated with subsequent combustible cigarette smoking. Evidence for the health and behavioural impact of dual use of e-cigarettes and combustible cigarettes is limited by imprecise measurement of exposure. Evidence on adults completely substituting combustible cigarettes for e-cigarettes is strong in clinical trials; observational studies do not show complete substitution. Finally, the effects of e-cigarette-related policy interventions to restrict e-cigarette consumption are currently limited in scope and too short-lived to draw causal inferences. Substantial evidence gaps related to the use, associated health impacts and regulation of e-cigarettes in the USA are identified, and we suggest key areas for future research to address that are crucial for informing the public health approach to e-cigarettes. WHAT THIS PAPER ADDS We synthesise published scientific reviews and selected studies published 2017–2024 on e-cigarette use on several outcomes. We synthesise published scientific reviews and selected studies published 2017–2024 on e-cigarette use on several outcomes. We identify knowledge gaps in the specificity of exposure measurement, insufficient longitudinal follow-up to assess long-term health consequences, heterogeneity of cessation effects from clinical trials versus observational studies, and limited scope of studies assessing policy effects. We identify knowledge gaps in the specificity of exposure measurement, insufficient longitudinal follow-up to assess long-term health consequences, heterogeneity of cessation effects from clinical trials versus observational studies, and limited scope of studies assessing policy effects. We provide several suggestions for necessary future research and call on the tobacco control community to address these gaps. We provide several suggestions for necessary future research and call on the tobacco control community to address these gaps. Introduction Electronic cigarettes (e-cigarettes or e-cigs) are a diverse class of tobacco products that have increased in popularity in the USA and have continued to evolve rapidly since their introduction in 2007.1 E-cigarettes are currently the second most popular tobacco products among US adults (18 years and older) after combustible cigarettes, with 4.5% reporting current (past-30 day) use in 20212; among young adults (ages 18–24), however, the prevalence of e-cigarette use was as high as 18.3% in 2021.2 Although rates of e-cigarette use among youth (ages 12–17) have declined from epidemic levels (in 2019, 27.5% of high school students reported using e-cigarettes3 down to 10% of high school students in 2023),4 youth e-cigarette use remains a concern. Nearly a decade after e-cigarettes were introduced in the USA, the US Food and Drug Administration (FDA) extended its tobacco regulatory authorities to include e-cigarettes in 20165; currently, many e-cigarettes remain on the market, pending decisions on Premarket Tobacco Product Applications (PMTAs).6 As of June 2024, an estimated 6300 unique products existed on the consumer marketplace,7 though this number may be even greater today. E-cigarettes vary in many ways (eg, nicotine content, flavour and other constituents, device power, and device type).1 Salt-based nicotine e-cigarettes, for example, are often able to deliver higher concentrations of nicotine to the user as they are formulated in a way that may make them more palatable than free-base nicotine products.1 Identifying and addressing evidence gaps is crucial to informing robust public health and regulatory policies. Although several reviews and summaries have been published on e-cigarette use to date,8–10 they have focused on specific topics (eg, health effects) or reported on data that are now several years old.11 This special communication serves as a review of evidence from existing systematic reviews and additional emerging topics not covered in reviews that were published between January 2017 and January 2024. Here, we identify evidence gaps related to five broad domains: health-related outcomes associated with e-cigarette use; initiation and use of e-cigarettes among youth and young adults; concurrent use of e-cigarettes and combustible cigarettes among youth and adults; transitions from combustible cigarette use to exclusive e-cigarette use among adults who currently smoke cigarettes; and existing e-cigarette-related policy interventions. We acknowledge that the large heterogeneity in e-cigarettes within the USA presents a challenge in summarising the literature in a systematic way. Therefore, despite the potential usefulness of studies from other countries, given the considerable global variability in e-cigarette characteristics, heterogeneity in populations, and different regulatory environments, we focus here on studies conducted in the USA to limit other sources of variability. Methods Literature was searched through PubMed and Medline for systematic reviews, scoping reviews, meta-analyses and select primary research articles on emerging topics not covered in reviews published starting 1 January 2017 (indicative of the maturing of e-cigarette uptake in the USA over 2011–2016 and the introduction of salt-based nicotine e-cigarettes) to 1 January 2024. We included human studies of various designs and outcomes, though preclinical evidence presented as part of systematic reviews involving humans was also reviewed to supplement the evidence on clinical health outcomes. Given this was not a meta-analysis or systematic review and the many different study designs and outcomes, we did not formally assess the risk of biases nor quality of the evidence (see online supplemental appendices A and B for more on methods). Results Although several self-reported measures of e-cigarette use exist (eg, number of days used per month),12 our review found that these largely capture frequency but do not adequately capture intensity. Intensity is influenced by device/e-liquid characteristics and user behaviour, is often difficult to measure in observational studies, and there is considerable evidence that individuals have difficulty recalling or estimating these aspects.12 These measurement challenges are even more evident for ‘open-system’ e-cigarettes which allow the user to modify virtually every component part and/or fill them with any liquid.13 Therefore, the following findings should be interpreted with these fundamental measurement limitations in mind. Health outcomes associated with e-cigarette use E-cigarette use is associated with adverse effects on organ and cellular health in humans, animals and in vitro.14 Overall, e-cigarette use is associated with several acute adverse health outcomes, including acute respiratory effects (eg, increased shortness of breath, lung inflammation, respiratory infections, throat and mouth irritation, and asthma), cardiovascular conditions (eg, increased heart rate and blood pressure, arterial stiffness, impaired endothelial function, increased risk of myocardial infarction) and various other outcomes (eg, poisonings, risk of burns).15–18 The association between e-cigarette use and stroke is largely confounded by prior combustible tobacco use.19 Because the brain is not yet fully developed in youth and young adults, establishing nicotine dependence earlier in life may result in poorer mental health outcomes (eg, anxiety, depression) and neurological changes that result in greater nicotine dependence and escalation in substance use later in life.3 Decades of chronic e-cigarette use are needed to observe the lagged effects on several disease endpoints, so the long-term population effects of e-cigarette use are currently unclear. The long incubation period of many cancer types makes it difficult to connect e-cigarette exposure to cancer outcomes without long observation periods allowing follow-up (eg, following youth and young adults who use e-cigarettes into older adulthood). Biomarkers of exposure, collected through biological samples (eg, blood or urine), are currently being used to predict potential chronic health conditions and disease endpoints.20 21 Based on the findings from observational studies on biomarkers,20 21 two major conclusions can be drawn. First, concentrations of several tobacco exposure biomarkers, including tobacco specific nitrosamines, volatile organic compounds and metals, were higher in persons using e-cigarettes exclusively compared with non-users, which may translate to long-term risk of cancer, respiratory, developmental, and reproductive diseases. Second, most biomarkers were significantly lower among persons using e-cigarettes exclusively than among individuals who currently smoked cigarettes. Together, these findings suggest that use of e-cigarettes presents health risks, but the known risks for exclusive e-cigarette use among those who have formerly smoked cigarettes may be lower compared with those continuing to smoke cigarettes.20–22 The literature on evaluating health outcomes associated with e-cigarette use is limited in several ways. First, there is conclusive evidence that toxins emitted from e-cigarettes are highly variable and depend on device and e-liquid characteristics and user behaviour,23 but these aspects are often inadequately captured in many of the data sources of studies reviewed here. Second, associations between e-cigarettes and health outcomes were often confounded by the strong influence of concurrent or prior combustible tobacco use. Third, existing studies are based on relatively short-term observations that preclude documenting actual endpoints for chronic diseases; no long-term toxicological/safety studies of e-cigarette use have been documented yet in humans. Fourth, given the variety of ingredients in the thousands of different products on the market, this research is exceptionally difficult to pursue in a systematic fashion; findings from various studies may not be comparable and generalisable, and compounds that are not listed on e-liquid labels have also been discovered in e-liquids.24 Fifth, there are currently no e-cigarette-specific biomarkers of exposure and much remains unknown about the long-term health effects of inhaling other compounds found in e-liquids (eg, flavourants). Many e-cigarette flavours are also food additives and scents used in cosmetics; however, the health impact of inhaling these compounds at the levels found in e-cigarettes over time is uncertain, though there is initial evidence of pulmonary toxicological effects14 and endothelial dysfunction.25 Still, e-cigarette liquids involve many different combinations of chemically unstable compounds that may have novel toxicological effects.24 Finally, most clinical biomarker studies are manufacturer funded, which could lead to publication bias.21 Risks of e-cigarette initiation and use among youth and young adults Most tobacco initiation and nicotine dependence are established in adolescence, 26 27and therefore, the vast majority of studies on initiation have focused on youth. Initiation is often motivated by curiosity and peer influence, social media marketing, perception of e-cigarettes as a less harmful and less addictive alternative to cigarettes, industry marketing targeting youth and the emergence of new and more efficient nicotine delivery systems.28 Most relevant to youth initiation is the availability of appealing e-cigarette flavours,29 such as candy and dessert flavours, fruit and mint/menthol, flavours also associated with decreased harm perceptions as compared with tobacco flavours.30 Several other e-cigarette characteristics may appeal to youth and young adults (eg, attractive colours, sleek designs, low odour/vapour levels).28 Youth using newer generation e-cigarettes are more likely to vape daily and show greater nicotine dependence symptoms than youth using earlier generation e-cigarettes.31 Even low-level e-cigarette use in early adolescence may increase the risk of escalated use later, with a younger age of initiation of e-cigarette use predicting greater e-cigarette use intensity.32 There is also emerging evidence that e-cigarette use by youth who do not currently smoke is associated with increased odds of subsequent combustible cigarette smoking initiation later in life and dual use of e-cigarettes and cigarettes.23 33–35 Several longitudinal studies have reported associations between e-cigarette use and subsequent cigarette smoking initiation among youth who would not have initiated cigarette smoking otherwise.35 36 However, at the same time, trends in population data do not show increases in cigarette use among youth or young adults,37 38 and evidence suggests continued declines in combustible cigarette use are independent from the uptake of e-cigarettes among youth.39 More methodologically rigorous studies are needed to disentangle whether the observed associations between e-cigarette uptake and changes in cigarette use at the population level are related or independent. If related, there is a need to identify whether the relationship supports replacement or substitution of e-cigarettes for combustible cigarettes among youth, a gateway hypothesis (ie, e-cigarettes lead to progression to combustible cigarette use), and/or a common liability that predicts tobacco use generally.40 The literature on determining the risks of e-cigarette initiation and use among youth and young adults is limited in several ways. There is currently limited evidence on whether youth who initiate e-cigarettes continue use into young adulthood. More evidence on the longitudinal trajectory of e-cigarette use, as well as the frequency and intensity of e-cigarette use (eg, escalation in use), and if and/or how youth and young adults become established dual users of e-cigarettes and other tobacco products is necessary. Finally, there is emerging evidence of increased e-cigarette initiation among young adults without a prior history of tobacco use,41 42 but it is unclear whether youth who started e-cigarettes are continuing using in young adulthood (cohort effect) and/or whether young adults who used tobacco are starting at later ages. Concurrent use of e-cigarettes and combustible cigarettes There are varying definitions of concurrent use (encompassing dual/poly/multiple tobacco product use) across studies, likely contributing to heterogeneity in the measures of concurrent use and its derived variables in the existing literature.12 43 This lack of uniform and comparable measures also makes it challenging to make strong conclusions on outcomes related to concurrent use. In the USA, approximately 3.4% of adults, 4.8% of young adults and 3.4% of youth reported currently using multiple tobacco products.4 44 This mostly reflects the use of e-cigarettes with cigarettes or cigarillos, with nearly one-third of individuals who reported current use of tobacco products reporting use of both e-cigarettes and cigarettes, a trend increasing over time.45 There are a limited number of systematic reviews on this topic. Emerging evidence suggests roughly half of adults concurrently using e-cigarettes and combustible cigarettes continue doing so after a year’s follow-up,46 and another study found persistent dual use of e-cigarettes and cigarettes for multiple years.47 While some research shows dual use may transition to exclusive e-cigarette use,48 other evidence suggests that e-cigarette use may lead to overall greater tobacco use and an increased likelihood of sustained dual use.46 In addition, individuals without prior tobacco product use who use e-cigarettes are more likely to initiate cigarette smoking than those individuals who do not use e-cigarettes, and individuals who formerly smoked cigarettes and currently use e-cigarettes are twice as likely to relapse to cigarette smoking than those who do not use e-cigarettes.9 33 49–51 People concurrently using e-cigarettes and combustible cigarettes may also be exposed to more toxicants than individuals reporting exclusive cigarette use.22 The literature on the concurrent use of e-cigarettes and combustible cigarettes is limited in several ways. Importantly, measurement of concurrent use is limited by current measures of e-cigarette use12 and often lacks information on how frequently individuals use each product (eg, ratio of e-cigarette consumption to cigarettes) and for how long individuals continue to use both products. Furthermore, concurrent use remains largely understudied among all populations, including the identification of demographic and other relevant characteristics (eg, situational contexts) that predict multiple tobacco product use.45 Transitions from combustible cigarette use to exclusive e-cigarette use among adults who currently smoke A review of observational studies in ‘real-world’ population-based samples found that use of e-cigarettes as consumer products is not associated with substitution of e-cigarettes for combustible cigarette smoking.52 These findings were consistent even among those who reported they were motivated to quit smoking combustible cigarettes. However, daily e-cigarette use was associated more with quitting combustible cigarettes than less-than-daily use.52 Research in clinical trials shows high-certainty evidence that providing nicotine-containing e-cigarettes was as effective in promoting cessation from combustible cigarettes as some FDA-approved cessation medications.53 Furthermore, prescribed e-cigarette use was associated with greater combustible cigarette cessation than nicotine replacement therapies and non-nicotine e-cigarettes, with estimates of 5–8 additional quitters per 100 persons53 (see also Ashour and Wanget al10 52 for review). There is, however, evidence that individuals who used e-cigarettes compared with FDA-approved cessation medications to quit smoking combustible cigarettes often did not discontinue using all tobacco products completely; further, individuals may be more prone to cigarette smoking relapse than if they had used FDA-approved cessation medications, given their continued dependence on nicotine.53 The literature on transitions from combustible cigarette use to exclusive e-cigarette use among adults is limited in several ways. Differences in study designs and contexts between observational and clinical studies limit comparability and generalisability of the results from these two types of studies. For example, clinical trials often test specific e-cigarette product(s), whereas observational studies involve collapsing outcomes across many different e-cigarette products. In addition, data from clinical trials can be claimed as causal, whereas observational studies are primarily associational. Existing e-cigarette-related policy interventions Comprehensive tobacco control policies (eg, combinations of taxation/price increases and social programmes) have proven effective in reducing the prevalence of tobacco use worldwide.54 Approaches for regulating e-cigarettes in the USA to date have been mostly at the state and local level; many of these have been relatively narrow in scope, resulting in a negligible impact on reducing e-cigarette use among the younger population and accompanied by some unintended consequences (see O’Connell and Kephart and Reiter et al,55 56 for further discussion). As a result, much of the evaluation of US policies regulating e-cigarettes is ongoing and there are few systematic reviews. Though perhaps the most widespread intervention, there is currently insufficient evidence that minimum legal sales age (MLSA) laws alone have reduced youth e-cigarette use.56 Some studies found decreases in youth e-cigarette use,57 58 while others reported that these laws were associated with increases in e-cigarette use59 and initial increases in cigarette smoking58 among youth. Flavour restrictions have been implemented at the federal, state and local levels with some success in reducing youth e-cigarette use.56 At the federal level, the US FDA announced in February 2020 increased enforcement action against certain unauthorised flavoured cartridge-based e-cigarettes. This action was associated with increased e-cigarette quit intentions and cessation among youth in particular,60 61 and initial decreased flavoured e-cigarette sales,61 62 but also switching to other exempt e-cigarettes (eg, disposable e-cigarettes), other flavours (eg, from mint to menthol), and temporarily to combustible tobacco products.60 63 64 A number of states (eg, California, Massachusetts) and local jurisdictions have also adopted restrictions on the sale of flavoured e-cigarettes65; these have been associated with reductions in e-cigarette sales at varying degrees depending on retailer compliance and enforcement.66 67 In September 2020, the FDA initiated a substantive review of e-cigarette PMTAs, a regulatory pathway required to market new tobacco products as consumer products. As of August 2024, 34 e-cigarette products have been authorised for legal marketing and hundreds of e-cigarettes have been issued marketing denial orders; still, the market includes thousands of products that are being sold illegally.68 69 Limitations to the e-cigarette-related policy interventions literature have been that most efforts are piecemeal; several unintended consequences are likely a result of isolated policy initiatives that did not account for the tobacco landscape and compensatory behaviours. Furthermore, while policies have been developing or considered, e-cigarettes have continued to evolve rapidly. Conclusions and recommendations for future research Based on the status of the current scientific literature on e-cigarettes, we have made several observations. First, current measures of e-cigarette use vary widely and lack specificity across studies reviewed here. E-cigarette products are most often treated as a homogenous class, and product specifics (eg, device model/type, nicotine concentration) and use intensity are often not characterised. This impacts the generalisability and time sensitivity of conclusions in every area. Second, the long-term health consequences of e-cigarette use, trajectories of initiation, dual-use and transitions away from combustible cigarettes, and the impact of e-cigarette policy interventions and regulations on e-cigarette use at the population level all have large knowledge gaps that present significant challenges for the public health community, including substantial regulation lag. Given these many unknowns, we make the following set of recommendations for future research: E-cigarettes are a very polarising topic within the tobacco control community, and continued efforts must be made to identify and reduce bias in scientific research and conclusions. One of the most obvious is commercial interest in the outcomes of studies. For example, we noted that most clinical biomarker studies were manufacturer funded.21 Still, strong ideological differences between research groups too may bias studies and conclusions. There is an urgent need to encourage more collaborative research from those holding different views on the potential public health impacts of e-cigarettes. For example, resolving disputed research questions via an adversarial collaborative approach, rooted in an open science framework, can encourage researchers to agree on critical research questions and the data and statistical analyses required to address them.70 E-cigarettes are a very polarising topic within the tobacco control community, and continued efforts must be made to identify and reduce bias in scientific research and conclusions. One of the most obvious is commercial interest in the outcomes of studies. For example, we noted that most clinical biomarker studies were manufacturer funded.21 Still, strong ideological differences between research groups too may bias studies and conclusions. There is an urgent need to encourage more collaborative research from those holding different views on the potential public health impacts of e-cigarettes. For example, resolving disputed research questions via an adversarial collaborative approach, rooted in an open science framework, can encourage researchers to agree on critical research questions and the data and statistical analyses required to address them.70 Continued efforts should be made to characterise e-cigarette use intensity in studies. This is especially challenging given the substantial heterogeneity of e-cigarettes as products and how e-cigarette use tends to occur intermittently in many ‘sessions’ throughout a day.12 One possibility is for surveys to ask individuals to upload images of the products they use and/or provide videos of themselves using the products to allow researchers to estimate aspects of user behaviour (eg, puff duration), as well as use methods like ecological momentary assessment to reduce recall bias.71 Continued efforts should be made to characterise e-cigarette use intensity in studies. This is especially challenging given the substantial heterogeneity of e-cigarettes as products and how e-cigarette use tends to occur intermittently in many ‘sessions’ throughout a day.12 One possibility is for surveys to ask individuals to upload images of the products they use and/or provide videos of themselves using the products to allow researchers to estimate aspects of user behaviour (eg, puff duration), as well as use methods like ecological momentary assessment to reduce recall bias.71 The extreme heterogeneity of e-cigarette products and user behaviour (including current or former multiple tobacco product use) presents significant challenges in understanding chronic health and disease risks of e-cigarette use. The health impact of inhaling flavourants and other e-liquid compounds at the levels found in e-cigarettes over time is unknown, and the many different compounds in different e-cigarettes may have novel toxicological effects. Continued exposure studies (including preclinical) and identifying biomarkers unique to e-cigarette use are necessary steps to address these gaps. The extreme heterogeneity of e-cigarette products and user behaviour (including current or former multiple tobacco product use) presents significant challenges in understanding chronic health and disease risks of e-cigarette use. The health impact of inhaling flavourants and other e-liquid compounds at the levels found in e-cigarettes over time is unknown, and the many different compounds in different e-cigarettes may have novel toxicological effects. Continued exposure studies (including preclinical) and identifying biomarkers unique to e-cigarette use are necessary steps to address these gaps. Many measures of concurrent use do not precisely capture the ratio of cigarette to e-cigarette use. Future research should more precisely quantify dual and poly tobacco use, as understanding these use patterns has health and regulatory implications. Finally, more longitudinal research is necessary to understand the persistence of dual use status, as well as sociodemographic and environmental/economic factors underlying dual (and poly) use. Many measures of concurrent use do not precisely capture the ratio of cigarette to e-cigarette use. Future research should more precisely quantify dual and poly tobacco use, as understanding these use patterns has health and regulatory implications. Finally, more longitudinal research is necessary to understand the persistence of dual use status, as well as sociodemographic and environmental/economic factors underlying dual (and poly) use. Although it appears that the findings from observational studies and clinical trials are conflicting, each study type could inform different regulatory pathways (ie, the FDA’s Center for Tobacco Products (CTP) regulates e-cigarettes as consumer products whereas the FDA’s Center for Drug Evaluation and Research regulates cessation medications) and which route(s) may have the most optimal public health benefit. Pragmatic trials testing if interventions in clinical trials can translate into clinical practice and/or what components of clinical interventions are crucial in the natural environment to obtain similar results are needed. Similarly, e-cigarettes and their role in transitioning people from combustible cigarettes when used as consumer products, without prescription and professional supervision, should continue to be studied through carefully controlled observations. Although it appears that the findings from observational studies and clinical trials are conflicting, each study type could inform different regulatory pathways (ie, the FDA’s Center for Tobacco Products (CTP) regulates e-cigarettes as consumer products whereas the FDA’s Center for Drug Evaluation and Research regulates cessation medications) and which route(s) may have the most optimal public health benefit. Pragmatic trials testing if interventions in clinical trials can translate into clinical practice and/or what components of clinical interventions are crucial in the natural environment to obtain similar results are needed. Similarly, e-cigarettes and their role in transitioning people from combustible cigarettes when used as consumer products, without prescription and professional supervision, should continue to be studied through carefully controlled observations. Flavour restrictions have been associated with some reductions in e-cigarette sales at the state and local level; however, many stand-alone policy interventions have thus far proven ineffective. Perhaps the most widespread intervention, minimum age restrictions, have alone failed to reduce youth e-cigarette use56 but may be more effective if combined with other initiatives. Comprehensive policies (eg, involving taxation, price increases and social programmes) have historically done more to reduce tobacco consumption than any strategy alone. Such policies applied to e-cigarettes may be explored via population-level simulation models to aid in instilling synergy in tobacco control policies that address the current tobacco marketplace as a whole. Finally, it may also be beneficial to consider the successes and failures of countries outside of the USA in regulating e-cigarettes; though many differences exist in the regulatory environments and populations, considering the approaches of other countries may be at least somewhat instructive. For example, Australia’s experiment with prescription e-cigarettes may provide lessons on intended and unintended consequences.72 Similarly, considering research on the effectiveness of different policies towards illicit drugs may also prove instructive, especially regarding e-cigarette restrictions.73 Flavour restrictions have been associated with some reductions in e-cigarette sales at the state and local level; however, many stand-alone policy interventions have thus far proven ineffective. Perhaps the most widespread intervention, minimum age restrictions, have alone failed to reduce youth e-cigarette use56 but may be more effective if combined with other initiatives. Comprehensive policies (eg, involving taxation, price increases and social programmes) have historically done more to reduce tobacco consumption than any strategy alone. Such policies applied to e-cigarettes may be explored via population-level simulation models to aid in instilling synergy in tobacco control policies that address the current tobacco marketplace as a whole. Finally, it may also be beneficial to consider the successes and failures of countries outside of the USA in regulating e-cigarettes; though many differences exist in the regulatory environments and populations, considering the approaches of other countries may be at least somewhat instructive. For example, Australia’s experiment with prescription e-cigarettes may provide lessons on intended and unintended consequences.72 Similarly, considering research on the effectiveness of different policies towards illicit drugs may also prove instructive, especially regarding e-cigarette restrictions.73 There are several limitations to our analyses that are worth noting here. First, there is substantial heterogeneity in e-cigarette products and user behaviour. Treating these products as a single class of products, as most of the literature reviewed does, is suboptimal and results in an absence of product-specific outcomes. Second, although we tried to acknowledge limitations of the reviewed studies, there were many different measures, outcomes and study designs, all of which can be biased by poor measurement of exposures and unmeasured confounders. Third, the conclusions drawn from published research may correspond to products that are outdated, especially given the ever-changing nature of these products and the market. Conclusions Substantial knowledge gaps exist regarding fundamental aspects of e-cigarette use, including precise measurement of e-cigarette product characteristics and behavioural use patterns and remaining unknowns regarding the long-term health consequences associated with e-cigarette use. It is, therefore, crucial that the tobacco research community addresses these gaps with scientific evidence free from biases to inform policy and advise the public on how to make informed decisions about e-cigarette use. Supplementary material